#United States #Seattle #Caris Life Sciences #Precision Medicine #SGO Annual Meeting

Caris Life Sciences to Present Innovative Research at the SGO Annual Meeting

Caris Life Sciences®, a prominent player in the AI TechBio field and a pioneer in precision medicine, is set to unveil significant research findings at the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, scheduled for March 14-17, 2025, in Seattle, Washington. The company's participation highlights its commitment to advancing the field of gynecological oncology through innovative research and collaboration.

During the meeting, Caris, along with its partners from the Caris Precision Oncology Alliance™, will present five pivotal studies focusing on various gynecological tumor types. These presentations will showcase the transformative potential of comprehensive molecular profiling in understanding cancer, with hopes of enhancing patient outcomes and optimizing treatment approaches.

Key Presentations and Findings

• - Oral Presentations:

1. Improved Real-World Outcomes in Patients with Low-Grade Serous Ovarian Carcinoma: This presentation will discuss how patients with MAPK pathway mutations benefitted from treatment with Trametinib.
2. Impact of CCNE1 Amplification: This study will analyze how CCNE1 amplification affects molecular signatures and outcomes in patients with High Grade Serous Ovarian and Endometrial Cancer.

• - Featured Poster Presentations:

1. Genomic and Immunohistochemical Characterization of NSMP Endometrial Cancer: A novel approach discussing estrogen receptor positivity.
2. GPR171 as a Prognostic Marker: This project investigates the implications of GPR171 on survival rates in cervical cancer.
3. Comparison of HER2 IHC Scoring Criteria: This poster will evaluate differences in the assessment of endometrial carcinoma.

These findings are significant as they illuminate new ways of understanding tumor biology. According to Dr. George W. Sledge, Jr., Caris’ EVP and Chief Medical Officer, “Our studies underscore the importance of molecular profiling and biomarkers in tailoring treatment to individual patients, thereby enhancing both prognosis and treatment effectiveness.”

The Role of the Caris Precision Oncology Alliance

The Caris POA consists of 96 cancer centers, including 47 NCI-designated centers, all collaborating to enhance precision oncology practices. This cross-institutional partnership aims to establish standards for molecular testing and leverage cutting-edge research to improve clinical outcomes for cancer patients. Caris continues to play an essential role by developing and providing innovative solutions that can revolutionize healthcare delivery.

About Caris Life Sciences

Caris Life Sciences is at the forefront of precision medicine, utilizing comprehensive molecular profiling techniques like Whole Exome and Whole Transcriptome Sequencing. With a combination of AI algorithms and vast databases, Caris works to unravel the complexities of diseases and deliver personalized solutions to patients. The company continues to expand its reach, with offices in major global cities including Phoenix, New York, Cambridge, Tokyo, and Basel. Caris is dedicated to realizing the potential of precision medicine for the betterment of human health.

In anticipation of the SGO Annual Meeting, Caris invites all attendees to visit their booth #416 for further insights into their research and innovations. For more in-depth details about the studies and the ongoing contributions to the field of oncology, visit the Caris Life Sciences website after the presentations for comprehensive abstracts and findings.

Conclusion

The forthcoming SGO Annual Meeting represents a significant opportunity for Caris Life Sciences to cement its position as a leader in gynecological cancer research and treatment. The company’s focus on molecular profiling aligns perfectly with the evolving landscape of precision medicine, establishing new benchmarks for cancer care and treatment personalization that could lead to improved outcomes for patients worldwide.